Enhertu, which Korean breast cancer patients urged for quick permission last year, was released in Korea this month. Analysts say that it will change the paradigm of secondary treatment for HER2-positive breast cancer with a superior effect compared to existing treatments. Daiichi Sankyo held a press conference at the Westin Chosun Hotel on the 12th to commemorate the launch of the ADC (antibody-drug conjugation) new drug Enhertu in Korea. Enhertu is an anticancer new drug approved by the Ministry of Food and Drug Safety in September last year. It can be used for HER2-positive breast cancer (secondary) and stomach cancer (third).

Enhertu is a next-generation ADC jointly developed by AstraZeneca